Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Blood

Volumn 118, Issue 3, 2011, Pages 757-765

  Ulrichts, Hans ^a   Silence, Karen ^a   Schoolmeester, Anne ^a   De Jaegere, Peter ^b   Rossenu, Stefaan ^a   Roodt, Jan ^c   Priem, Sofie ^a   Lauwereys, Marc ^a   Casteels, Peter ^a   Van Bockstaele, Femke ^a   Verschueren, Katrien ^a   Stanssens, Patrick ^a   Baumeister, Judith ^a   Holz, Josefin Beate ^a  

^a ABLYNX NV   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADRENALIN; ALX 0081; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; GLYCOPROTEIN IB; HEPARIN; IODINE 125; LYSINE ACETYLSALICYLATE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; ISOTOPE LABELING; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 79960058122     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-317859     Document Type: Article

References (49)

1. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15-28. (Pubitemid 37361621)
2. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov. 2003;2(10):775-789.
3. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80(3):512-518. (Pubitemid 28438751)
4. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006;81(4):518-526.
5. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem. 2000;275(11):7539-7546.
6. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of theA1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem. 1991;196(2):369-375.
7. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-1459. (Pubitemid 351501497)
8. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87(4):1234-1240.
9. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987;69(2):625-628. (Pubitemid 17022038)
10. Andre P, Hainaud P, Bal dit SC, Garfinkel LI, Caen JP, Drouet LO. Relative involvement of GPIb/IX-vWF axis and GPIIb/IIIa in thrombus growth at high shear rates in the guinea pig. Arterioscler Thromb Vasc Biol. 1997;17(5):919-924.
11. Kawasaki T, Kaku S, Kohinata T, et al. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo. Am J Hematol. 1994;47(1):6-15. (Pubitemid 24261138)
12. Strony J, Phillips M, Brands D, Moake J, Adelman B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation. 1990;81(3):1106-1114. (Pubitemid 20090410)
13. Azzam K, Garfinkel LI, Bal dit SC, Cisse TM, Drouet L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb Haemost. 1995;73(2):318-323.
14. Gurevitz O, Goldfarb A, Hod H, et al. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler Thromb Vasc Biol. 1998;18(2):200-207. (Pubitemid 28277596)
15. McGhie AI, McNatt J, Ezov N, et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation. 1994;90(6):2976-2981.
16. Yao SK, Ober JC, Garfinkel LI, et al. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation. 1994;89(6):2822-2828. (Pubitemid 24173704)
17. Hennan JK, Swillo RE, Morgan GA, et al. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost. 2006;95(3):469-475.
18. Wadanoli M, Sako D, Shaw GD, et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost. 2007;98(2):397-405. (Pubitemid 47260291)
19. Bellinger DA, Nichols TC, Read MS, et al. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A. 1987;84(22):8100-8104.
20. Cadroy Y, Hanson SR, Kelly AB, et al. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood. 1994;83(11):3218-3224. (Pubitemid 24158466)
21. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122(1):165-171. (Pubitemid 27376034)
22. Kageyama S, Yamamoto H, Yoshimoto R. Antihuman von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler Thromb Vasc Biol. 2000;20(10):2303-2308.
23. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res. 2001;101(5):395-404. (Pubitemid 32280850)
24. Kageyama S, Yamamoto H, Nakazawa H, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22(1):187-192. (Pubitemid 34076252)
25. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol. 2002;443(1-3):143-149. (Pubitemid 34603609)
26. Krupski WC, Bass A, Cadroy Y, Kelly AB, Harker LA, Hanson SR. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates. Surgery. 1992;112(2):433-439.
27. Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost. 1998;79(1):202-210. (Pubitemid 28037082)
28. Diener JL, Daniel Lagasse HA, Duerschmied D, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the antivon Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009;7(7):1155-1162.
29. Gurevitz O, Eldar M, Skutelsky E, et al. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. Thromb Haemost. 2000;84(5):912-917.
30. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116(23):2678-2686. (Pubitemid 350291240)
31. Machin S, Clarke C, Ikemura O, et al. A humanized monoclonal antibody against vWF A1 domain inhibits vWF: RiCof activity and platelet adhesion in human volunteers [abstract]. J Thromb Haemost. 2003;(suppl 1):Abstract OC328.
32. Bartunek J, Barbato E, Vercruysse K, et al. Safety and efficacy of anti-von Willebrand factor Nanobody ALX-0081 in stable angina patients undergoing percutaneous coronary intervention [abstract]. Circulation. 2010;122:Abstract 15084.
33. Bartunek J, Barbato E, Holz J-B, Vercruysse K, Ulrichts H, Heyndrickx G. ALX-0081 a novel antithrombotic: results of a single-dose phase 1 study in healthy volunteers and further development in patients with stable angina [abstract]. Circulation. 2008;118:Abstract 2009.
34. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446-448. (Pubitemid 23179389)
35. Van Bockstaele F, Holz J-B, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs. 2009;10(11):1212-1224.
36. Yao SK, McNatt J, Cui K, et al. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endotheliuminjured arteries in nonhuman primates. Circulation. 1993;88(6):2888-2893. (Pubitemid 23360216)
37. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(6 suppl):IV3-IV14.
38. Fontayne A, Meiring M, Lamprecht S, et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost. 2008;100(4):670-677.
39. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22(2):323-328. (Pubitemid 34127047)
40. Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99(10):3623-3628. (Pubitemid 34534531)
41. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest. 1996;26(5):353-370. (Pubitemid 26171949)
42. Benedict CR, Ryan J, Wolitzky B, et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 1991;88(5):1760-1765.
43. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation. 1997;96(7):2339-2347. (Pubitemid 27425842)
44. van Zanten GH, de GS, Slootweg PJ, et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest. 1994;93(2):615-632.
45. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996;88(5):1525-1541. (Pubitemid 26307046)
46. van Loon J, de Jaegere P, Ulrichts H, et al. The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing PCI [published online ahead of print June 9, 2011]. Thromb Haemost. doi:10.1160/TH10-12-0804.
47. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279(13):12102-12109. (Pubitemid 38445774)
48. Gorog DA, Douglas H, Ahmed N, Lefroy DC, Davies GJ. Coronary angioplasty enhances platelet reactivity through von Willebrand factor release. Heart. 2003;89(3):329-330. (Pubitemid 36241554)
49. Sakai H, Goto S, Kim JY, et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost. 2000;84(2):204-209. (Pubitemid 30601464)